Publication: Model-Informed Drug Development for Malaria Therapeutics
Issued Date
2018-01-06
Resource Type
ISSN
15454304
03621642
03621642
Other identifier(s)
2-s2.0-85040632198
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annual Review of Pharmacology and Toxicology. Vol.58, (2018), 567-582
Suggested Citation
Kayla Ann Andrews, David Wesche, James McCarthy, Jörg J. Möhrle, Joel Tarning, Luann Phillips, Steven Kern, Thaddeus Grasela Model-Informed Drug Development for Malaria Therapeutics. Annual Review of Pharmacology and Toxicology. Vol.58, (2018), 567-582. doi:10.1146/annurev-pharmtox-010715-103429 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/47328
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Model-Informed Drug Development for Malaria Therapeutics
Abstract
© 2018 Kayla Ann Andrews et al. Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries. Owing to the development of resistance toward current therapies, novel approaches to accelerate the development efforts of new malaria therapeutics are urgently needed. There have been significant advancements in the development of in vitro and in vivo experiments that generate data used to inform decisions about the potential merit of new compounds. A comprehensive disease-drug model capable of integrating discrete data from different preclinical and clinical components would be a valuable tool across all stages of drug development. This could have an enormous impact on the otherwise slow and resource-intensive process of traditional clinical drug development.